British pharmaceutical giant AstraZeneca said Monday that the trials of the coronavirus vaccine pioneered by the University of Oxford showed “encouraging” reactions among the elderly and young participants.
According to an update from Oxford, the potential vaccine, one of the 10 worldwide in the most advanced stage III of the experiments, showed “strong immune responses” in all groups of adults in the previous stage.
An AstraZeneca spokesman said the initial results “further build the body of evidence for the safety and immunogenicity” of its experimental vaccine.
“It is encouraging to see immunogenicity responses were similar between older and younger adults, the spokesman added.
The positive news is that Oxford’s submission of the essay in a medical journal for peer review II. It was revealed in data on the safety and immune responses of stage-stage participants.
It includes results for UK volunteers aged 56-69 and over 70, and the official release of data expected in the “coming weeks”.
“Our ongoing trials will provide further data, but this marks a key milestone and reassures us that the vaccine is safe for use and induces strong immune responses in both parts of the immune system in all adult groups,” the university said.
Oxford and AstraZeneca have been testing potential vaccines in various countries around the world for months.
It was suspended around the world on September 6 after a participant’s illness, but resumed soon after in the UK and in South Africa, Brazil, and Japan over the following weeks.
Authorities determined that the disease was not vaccine-related, and the U.S. Food and Drug Administration also allowed it to be restarted in the United States over the weekend.
The AstraZeneca / Oxford vaccine is one of the most promising and advanced vaccines in the world to fight the global pandemic that currently costs 1.1 million lives.
Many countries are confident to use this to vaccinate their populations.
The drug maker has pre-sold hundreds of millions of doses on several continents and has signed partnership agreements with other manufacturers to ensure that doses are made locally.
UK Health Secretary Matt Hancock fueled optimism further on Monday and said in an interview that “much” of the once vaccine spread could happen in Britain before next summer.